Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01506960 · ClinicalTrials.gov registry record · Phase 4

Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque

A Phase 4 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 4
Development phase
64
Enrollment target

NCT01506960: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.

NCT01506960 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 64 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01506960, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 4
Development phase
64 participants
Enrollment target

Study Summary

The purpose of this study is to learn more about lipid rich plaque using Near Infrared Spectroscopy (NIRS)/Intravascular Ultrasound (IVUS) imaging in patients who have had coronary artery stenting and Optical coherence tomography (OCT) imaging.

Primary Outcome

Subjects are presenting for their clinically-indicated cardiac catheterization. NIRS/IVUS imaging will be done at the time of catheterization.

Interventions

  • DEVICE InfraReDx Lipiscan IVUS

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2012-01
Est. Completion 2012-06
Phase Phase 4
Massachusetts General Hospital

2,032 total trials

Why NCT01506960 stopped before completion

NCT01506960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 1 intervention - of which InfraReDx Lipiscan IVUS is the first listed.

NCT01506960 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01506960 about?

NCT01506960 is a clinical study titled "Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque". The purpose of this study is to learn more about lipid rich plaque using Near Infrared Spectroscopy (NIRS)/Intravascular Ultrasound (IVUS) imaging in patients who have had coronary artery stenting and Optical coherence tomography (OCT) imaging.

What is the current status of trial NCT01506960?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2012-01. Estimated completion is 2012-06.

What interventions are being tested in trial NCT01506960?

The interventions under investigation include: InfraReDx Lipiscan IVUS (DEVICE).

Who is sponsoring clinical trial NCT01506960?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01506960's enrollment target sits among peer trials

64 1098th of 2000 higher than 895 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01506960, the US trial registry maintained by the National Library of Medicine. NCT01506960 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.